Psychedelic-assisted therapy has been one of the most-covered mental-health stories of the past decade. A 2026 quantitative analysis by Evers and colleagues maps how media enthusiasm grew, peaked, and partially pulled back across major U.S. outlets — and how the coverage related to the actual evidence base for depression and PTSD.1 Research Highlights Psychedelic clinical …
Ketamine and its S-enantiomer esketamine (sold as Spravato) are now established treatments for treatment-resistant depression and acute suicidality. The standard safety pitch from sponsors and clinics: at single sub-anesthetic doses, in supervised settings, addiction risk is minimal. A new case report in BJPsych Open documents a patient for whom that pitch failed catastrophically — and …
Media coverage of psychedelics outpaces the trial evidence. MDMA-PTSD signals are large; psilocybin-depression effects shrink against active comparators.
Modern administrative cohorts find no dementia signal for ECT and link it to lower suicide and mortality. The supportive literature carries known biases worth flagging.